Literature DB >> 26178435

Cardiovascular pharmacogenomics: current status and future directions.

Dan M Roden1.   

Abstract

Drugs are widely used and highly effective in the treatment of heart disease. Nevertheless, in some instances, even drugs effective in a population display lack of efficacy or adverse drug reactions in individual patients, often in an apparently unpredictable fashion. This review summarizes the genomic factors now known to influence variability in responses to widely used cardiovascular drugs such as clopidogrel, warfarin, heparin and statins. Genomic approaches being used to discover new pathways in common cardiovascular diseases and thus potential new targets for drug development are described. Finally, the way in which this new information is likely to be used in an electronic medical record environment is discussed.

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 26178435      PMCID： PMC4849475          DOI： 10.1038/jhg.2015.78

Source DB:  PubMed          Journal:  J Hum Genet        ISSN： 1434-5161            Impact factor:   3.172


  83 in total

1.  Intronic variants in SLCO1B1 related to statin-induced myopathy are associated with the low-density lipoprotein cholesterol response to statins in Chinese patients with hyperlipidaemia.

Authors:  Miao Hu; Valiant W L Mak; Brian Tomlinson
Journal:  Pharmacogenet Genomics       Date:  2012-11       Impact factor: 2.089

Review 2.  Population differences in major functional polymorphisms of pharmacokinetics/pharmacodynamics-related genes in Eastern Asians and Europeans: implications in the clinical trials for novel drug development.

Authors:  Kouichi Kurose; Emiko Sugiyama; Yoshiro Saito
Journal:  Drug Metab Pharmacokinet       Date:  2011-11-29       Impact factor: 3.614

3.  Symptomatic response to antiarrhythmic drug therapy is modulated by a common single nucleotide polymorphism in atrial fibrillation.

Authors:  Babar Parvez; Joseph Vaglio; Shane Rowan; Raafia Muhammad; Gayle Kucera; Tanya Stubblefield; Shannon Carter; Dan Roden; Dawood Darbar
Journal:  J Am Coll Cardiol       Date:  2012-06-20       Impact factor: 24.094

4.  Suppression of phosphoinositide 3-kinase signaling and alteration of multiple ion currents in drug-induced long QT syndrome.

Authors:  Zhongju Lu; Chia-Yen C Wu; Ya-Ping Jiang; Lisa M Ballou; Chris Clausen; Ira S Cohen; Richard Z Lin
Journal:  Sci Transl Med       Date:  2012-04-25       Impact factor: 17.956

5.  A large candidate gene survey identifies the KCNE1 D85N polymorphism as a possible modulator of drug-induced torsades de pointes.

Authors:  Stefan Kääb; Dana C Crawford; Moritz F Sinner; Elijah R Behr; Prince J Kannankeril; Arthur A M Wilde; Connie R Bezzina; Eric Schulze-Bahr; Pascale Guicheney; Nanette H Bishopric; Robert J Myerburg; Jean-Jacques Schott; Arne Pfeufer; Britt-Maria Beckmann; Eimo Martens; Taifang Zhang; Birgit Stallmeyer; Sven Zumhagen; Isabelle Denjoy; Abdennasser Bardai; Isabelle C Van Gelder; Yalda Jamshidi; Chrysoula Dalageorgou; Vanessa Marshall; Steve Jeffery; Saad Shakir; A John Camm; Gerhard Steinbeck; Siegfried Perz; Peter Lichtner; Thomas Meitinger; Annette Peters; H-Erich Wichmann; Christiana Ingram; Yuki Bradford; Shannon Carter; Kris Norris; Marylyn D Ritchie; Alfred L George; Dan M Roden
Journal:  Circ Cardiovasc Genet       Date:  2011-11-18

6.  Meta-analysis identifies six new susceptibility loci for atrial fibrillation.

Authors:  Patrick T Ellinor; Kathryn L Lunetta; Christine M Albert; Nicole L Glazer; Marylyn D Ritchie; Albert V Smith; Dan E Arking; Martina Müller-Nurasyid; Bouwe P Krijthe; Steven A Lubitz; Joshua C Bis; Mina K Chung; Marcus Dörr; Kouichi Ozaki; Jason D Roberts; J Gustav Smith; Arne Pfeufer; Moritz F Sinner; Kurt Lohman; Jingzhong Ding; Nicholas L Smith; Jonathan D Smith; Michiel Rienstra; Kenneth M Rice; David R Van Wagoner; Jared W Magnani; Reza Wakili; Sebastian Clauss; Jerome I Rotter; Gerhard Steinbeck; Lenore J Launer; Robert W Davies; Matthew Borkovich; Tamara B Harris; Honghuang Lin; Uwe Völker; Henry Völzke; David J Milan; Albert Hofman; Eric Boerwinkle; Lin Y Chen; Elsayed Z Soliman; Benjamin F Voight; Guo Li; Aravinda Chakravarti; Michiaki Kubo; Usha B Tedrow; Lynda M Rose; Paul M Ridker; David Conen; Tatsuhiko Tsunoda; Tetsushi Furukawa; Nona Sotoodehnia; Siyan Xu; Naoyuki Kamatani; Daniel Levy; Yusuke Nakamura; Babar Parvez; Saagar Mahida; Karen L Furie; Jonathan Rosand; Raafia Muhammad; Bruce M Psaty; Thomas Meitinger; Siegfried Perz; H-Erich Wichmann; Jacqueline C M Witteman; W H Linda Kao; Sekar Kathiresan; Dan M Roden; Andre G Uitterlinden; Fernando Rivadeneira; Barbara McKnight; Marketa Sjögren; Anne B Newman; Yongmei Liu; Michael H Gollob; Olle Melander; Toshihiro Tanaka; Bruno H Ch Stricker; Stephan B Felix; Alvaro Alonso; Dawood Darbar; John Barnard; Daniel I Chasman; Susan R Heckbert; Emelia J Benjamin; Vilmundur Gudnason; Stefan Kääb
Journal:  Nat Genet       Date:  2012-04-29       Impact factor: 38.330

7.  Clopidogrel: a case for indication-specific pharmacogenetics.

Authors:  J A Johnson; D M Roden; L J Lesko; E Ashley; T E Klein; A R Shuldiner
Journal:  Clin Pharmacol Ther       Date:  2012-05       Impact factor: 6.875

8.  Predicting warfarin dosage in European-Americans and African-Americans using DNA samples linked to an electronic health record.

Authors:  Andrea H Ramirez; Yaping Shi; Jonathan S Schildcrout; Jessica T Delaney; Hua Xu; Matthew T Oetjens; Rebecca L Zuvich; Melissa A Basford; Erica Bowton; Min Jiang; Peter Speltz; Raquel Zink; James Cowan; Jill M Pulley; Marylyn D Ritchie; Daniel R Masys; Dan M Roden; Dana C Crawford; Joshua C Denny
Journal:  Pharmacogenomics       Date:  2012-02-13       Impact factor: 2.533

9.  The effect of novel promoter variants in MATE1 and MATE2 on the pharmacokinetics and pharmacodynamics of metformin.

Authors:  S L Stocker; K M Morrissey; S W Yee; R A Castro; L Xu; A Dahlin; A H Ramirez; D M Roden; R A Wilke; C A McCarty; R L Davis; C M Brett; K M Giacomini
Journal:  Clin Pharmacol Ther       Date:  2012-10-17       Impact factor: 6.875

10.  Operational implementation of prospective genotyping for personalized medicine: the design of the Vanderbilt PREDICT project.

Authors:  J M Pulley; J C Denny; J F Peterson; G R Bernard; C L Vnencak-Jones; A H Ramirez; J T Delaney; E Bowton; K Brothers; K Johnson; D C Crawford; J Schildcrout; D R Masys; H H Dilks; R A Wilke; E W Clayton; E Shultz; M Laposata; J McPherson; J N Jirjis; D M Roden
Journal:  Clin Pharmacol Ther       Date:  2012-05-16       Impact factor: 6.875
View more
  3 in total

Review 1.  Biomarkers in cardiovascular disease: Statistical assessment and section on key novel heart failure biomarkers.

Authors:  Ravi Dhingra; Ramachandran S Vasan
Journal:  Trends Cardiovasc Med       Date:  2016-07-28       Impact factor: 6.677

Review 2.  Improving medical students' knowledge of genetic disease: a review of current and emerging pedagogical practices.

Authors:  Michael J Wolyniak; Lynne T Bemis; Amy J Prunuske
Journal:  Adv Med Educ Pract       Date:  2015-10-29

3.  Identification of Small Molecule Inhibitors of Human As(III) S-Adenosylmethionine Methyltransferase (AS3MT).

Authors:  Hui Dong; Mahendra Madegowda; Adel Nefzi; Richard A Houghten; Marc A Giulianotti; Barry P Rosen
Journal:  Chem Res Toxicol       Date:  2015-12-06       Impact factor: 3.739
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.